|
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer.
|
19790231 |
2010 |
|
Prostate carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Analysis of information from public gene expression databases confirmed that co-expression of insulin receptor mRNA and IGF-I receptor mRNA is common in prostate cancer specimens.
|
18785179 |
2009 |
|
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Apigenin suppresses insulin-like growth factor I receptor signaling in human prostate cancer: an in vitro and in vivo study.
|
18726972 |
2009 |
|
Prostate carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Insulin-like growth factor-I receptor (IGF-IR) overexpression may play a role in prostate cancer progression.
|
19738069 |
2009 |
|
Prostate carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In addition, an inverse correlation between BRCA1 and IGF-IR levels was observed in the androgen receptor (AR)-negative prostate cancer-derived P69 and M12 cell lines.
|
19223505 |
2009 |
|
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
RGD |
Disruption of growth hormone signaling retards prostate carcinogenesis in the Probasin/TAg rat.
|
18079205 |
2008 |
|
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In human PCa, the lowest IGF-IR immunoreactivity group tended to have the lowest body mass index in both normal and PCa epithelium.
|
18175332 |
2008 |
|
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our results suggest statins are potent inhibitors of the IGF-1/IGF-1R system in prostate cancer cells and may be beneficial in prostate cancer treatment.
|
18489904 |
2008 |
|
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Inhibition of the IGF-IR or the Src-ERK pathway should be considered, therefore, as an adjuvant therapy in prostate cancer.
|
17875736 |
2007 |
|
Prostate carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Luteolin inhibited insulin-like growth factor 1 (IGF-1) induced activation of IGF-1R and AKT in prostate cancer PC-3 and DU145 cells.
|
17065200 |
2007 |
|
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
We previously showed that IGF1R knockdown blocked survival of prostate cancer cells in which Akt activation was deregulated by PTEN loss.
|
16715137 |
2006 |
|
Prostate carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Our observation that men who do not carry two copies of the IGF-IR (AGG)7 allele are at increased risk of prostate cancer merits further investigation.
|
17164371 |
2006 |
|
Prostate carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
These results support the concept of IGF1R targeting in prostate cancer, and indicate that PTEN loss does not render tumor cells refractory to this strategy.
|
15499378 |
2005 |
|
Prostate carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In this study, we show that androgens up-regulate insulin-like growth factor-I receptor (IGF-IR) expression and sensitize prostate cancer cells to the biological effects of IGF-I.
|
15753383 |
2005 |
|
Prostate carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.
|
15574769 |
2004 |
|
Prostate carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
IGF1R is overexpressed by prostate cancer compared with benign prostatic epithelium and IGF1R expression commonly persists in androgen-independent metastatic disease at levels comparable to those in the primary.
|
12581018 |
2003 |
|
Prostate carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).
|
11507082 |
2001 |